Ming‐Huang Chen

5.3k total citations
168 papers, 2.8k citations indexed

About

Ming‐Huang Chen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ming‐Huang Chen has authored 168 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 61 papers in Pulmonary and Respiratory Medicine and 58 papers in Surgery. Recurrent topics in Ming‐Huang Chen's work include Cholangiocarcinoma and Gallbladder Cancer Studies (39 papers), Gastric Cancer Management and Outcomes (30 papers) and Pancreatic and Hepatic Oncology Research (15 papers). Ming‐Huang Chen is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (39 papers), Gastric Cancer Management and Outcomes (30 papers) and Pancreatic and Hepatic Oncology Research (15 papers). Ming‐Huang Chen collaborates with scholars based in Taiwan, United States and China. Ming‐Huang Chen's co-authors include Yee Chao, Peter Mu‐Hsin Chang, Chun‐Yu Liu, Chun‐Nan Yeh, Chi‐Ying F. Huang, Yi‐Hsiang Huang, Ming‐Han Chen, Kin‐Lu Wong, Wen-Liang Fang and Michael Hsiao and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ming‐Huang Chen

161 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ming‐Huang Chen Taiwan 30 954 848 623 613 397 168 2.8k
Mamoru Uemura Japan 28 1.1k 1.1× 1.2k 1.4× 522 0.8× 903 1.5× 678 1.7× 247 3.4k
Charalambos Solomides United States 33 1.0k 1.1× 1.1k 1.3× 746 1.2× 484 0.8× 598 1.5× 89 3.2k
Lei Liang China 30 965 1.0× 1.4k 1.7× 486 0.8× 518 0.8× 945 2.4× 171 3.4k
Yi Jiang China 28 450 0.5× 891 1.1× 492 0.8× 399 0.7× 393 1.0× 151 2.4k
Chao‐Cheng Huang Taiwan 35 623 0.7× 1.3k 1.6× 471 0.8× 962 1.6× 694 1.7× 143 4.2k
Zheng Li China 32 1.2k 1.3× 1.3k 1.6× 843 1.4× 437 0.7× 700 1.8× 232 3.7k
Tae‐Yong Kim South Korea 26 1.4k 1.5× 626 0.7× 649 1.0× 433 0.7× 424 1.1× 125 2.4k
Wei He China 27 558 0.6× 1.3k 1.6× 526 0.8× 338 0.6× 797 2.0× 134 2.9k
Nan Zhang China 27 739 0.8× 728 0.9× 303 0.5× 438 0.7× 308 0.8× 170 2.4k
Taishi Hata Japan 30 1.2k 1.3× 1.1k 1.3× 495 0.8× 783 1.3× 826 2.1× 222 3.0k

Countries citing papers authored by Ming‐Huang Chen

Since Specialization
Citations

This map shows the geographic impact of Ming‐Huang Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming‐Huang Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming‐Huang Chen more than expected).

Fields of papers citing papers by Ming‐Huang Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming‐Huang Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming‐Huang Chen. The network helps show where Ming‐Huang Chen may publish in the future.

Co-authorship network of co-authors of Ming‐Huang Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Ming‐Huang Chen. A scholar is included among the top collaborators of Ming‐Huang Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming‐Huang Chen. Ming‐Huang Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Chien-Jung, Guan‐Ting Liu, Yu‐Chan Chang, et al.. (2025). Construction of hot tumor classification models in gastrointestinal cancers. Journal of Translational Medicine. 23(1). 218–218. 1 indexed citations
2.
Chen, Yen‐Hao, et al.. (2024). Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy. Hepatology International. 18(6). 1804–1814. 5 indexed citations
3.
Hung, Yi‐Ping, Pei‐Chang Lee, Yen‐Hwa Chang, et al.. (2024). Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas. Alimentary Pharmacology & Therapeutics. 61(3). 501–512. 3 indexed citations
4.
Tan, Kien Thiam, Li‐Yuan Bai, Chin‐Fu Hsiao, et al.. (2022). Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study. Clinical Cancer Research. 28(19). 4248–4257. 13 indexed citations
5.
Chang, Yu‐Chan, Ya-Chi Hung, Yi‐Ping Hung, et al.. (2022). A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer. Neoplasia. 35. 100856–100856. 11 indexed citations
6.
Li, Chung‐Pin, Yi‐Hsiang Huang, Shao‐Jung Hsu, et al.. (2022). Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. Cancers. 14(1). 218–218. 15 indexed citations
7.
Chiang, Nai‐Jung, Li‐Tzong Chen, Yan‐Shen Shan, Chun‐Nan Yeh, & Ming‐Huang Chen. (2021). Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules. 11(1). 97–97. 5 indexed citations
8.
Chang, Yu‐Chan, Chiao‐En Wu, Dennis Shin-Shian Hsu, et al.. (2021). Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. Biomedicines. 9(8). 885–885. 4 indexed citations
9.
Chang, Yu‐Chan, Ming‐Huang Chen, Chun‐Nan Yeh, & Michael Hsiao. (2020). Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. Biomolecules. 10(10). 1377–1377. 5 indexed citations
10.
Huang, Kuo‐Hung, Ming‐Huang Chen, Wen-Liang Fang, et al.. (2020). The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer. Cancers. 12(8). 2318–2318. 22 indexed citations
11.
Wu, Chiao‐En, Da‐Wei Yeh, Wen‐Kuan Huang, et al.. (2020). Chromosomal Instability May Not Be a Predictor for Immune Checkpoint Inhibitors from a Comprehensive Bioinformatics Analysis. Life. 10(11). 276–276. 12 indexed citations
12.
Huang, Wen-Sheng, Chi-Mu Chuang, Gann Ting, et al.. (2019). A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors. EJNMMI Research. 9(1). 46–46. 22 indexed citations
13.
He, Shuwen, Yu Liu, Yalong Wang, et al.. (2017). SKAP2 regulates Arp2/3 complex for actin-mediated asymmetric cytokinesis by interacting with WAVE2 in mouse oocytes. Cell Cycle. 16(23). 2272–2281. 8 indexed citations
14.
Chen, Ming‐Huang, Chi‐Tung Cheng, Ren‐Chin Wu, et al.. (2016). ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients. Clinical Cancer Research. 22(16). 4225–4235. 48 indexed citations
15.
Chen, Ming‐Huang, Johnson Lin, Chin‐Fu Hsiao, et al.. (2016). A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma. Medicine. 95(3). e2565–e2565. 32 indexed citations
16.
Lu, Hsueh‐Ju, Kuo-Wei Chen, Ming‐Huang Chen, et al.. (2013). Serum Albumin is an Important Prognostic Factor for Carotid Blowout Syndrome. Japanese Journal of Clinical Oncology. 43(5). 532–539. 6 indexed citations
17.
Chang, Peter Mu‐Hsin, Chun‐Yu Liu, Chih‐Yu Yang, et al.. (2011). Sunitinib-induced Nephrotic Syndrome in Association with Drug Response in a Patient with Xp11.2 Translocation Renal Cell Carcinoma. Japanese Journal of Clinical Oncology. 41(11). 1277–1281. 10 indexed citations
18.
19.
Chen, Ming‐Huang, Tzeon-Jye Chiou, Peng-Chan Lin, et al.. (2007). Comparison of Myeloablative and Nonmyeloablative Hematopoietic Stem Cell Transplantation for Treatment of Chronic Myeloid Leukemia. International Journal of Hematology. 86(3). 275–281. 7 indexed citations
20.
Tsai, Chih–Chien, et al.. (1994). Greater Enhancement of Chemosensitivity by Caffeine in High-p185neu-Expressing Human Non-Small-Cell Lung Cancer Cell Lines. JNCI Journal of the National Cancer Institute. 86(13). 1018–1020. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mamoru Uemura Breakdown of academic impact, for papers by Charalambos Solomides Breakdown of academic impact, for papers by Lei Liang Breakdown of academic impact, for papers by Yi Jiang Breakdown of academic impact, for papers by Chao‐Cheng Huang Breakdown of academic impact, for papers by Zheng Li Breakdown of academic impact, for papers by Tae‐Yong Kim Breakdown of academic impact, for papers by Wei He Breakdown of academic impact, for papers by Nan Zhang Breakdown of academic impact, for papers by Taishi Hata
Rankless by CCL
2026